Atheroma volume decreased annually by 2.4 ± 0.5 mm3 for patients treated with beta blockers while remaining unchanged for untreated patients. Results were adjusted for history of hypertension, angina, or MI.

Previous trials have shown that “beta blockers effectively reduce recurrent myocardial infarction, sudden cardiac death, and total mortality in patients with myocardial infarction,” according to the investigators (Ann Intern Med. 2007;147:10-18). However, this analysis stands as the first to demonstrate that beta blockers can slow the progression of coronary atherosclerosis.

Reducing plaque is one thing, but improving outcomes is another. And researchers were quick to point out that “no direct data exist about the amount of differential change in atheroma volume that is associated with better clinical outcomes.” Even so, beta blockers have “considerable coronary antiatherosclerotic effects,” wrote the investigators, and “our findings provide contemporary evidence that supports the use of beta blockers for treating coronary artery disease.”

ClinicalAdvisor.com is for nurse practitioners and physician assistants, offering the latest information on diagnosing, treating, managing, and preventing medical conditions typically seen in the office-based primary-care setting.

Find all of the news and departments you love from the print issue archived for easy online access, along with special Web-only content.